Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti-versus Pro-Tumoral Activities

被引:50
作者
Xiang, Zheng [1 ]
Tu, Wenwei [1 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Paediat & Adolescent Med, Lab Translat Immunol, Hong Kong, Hong Kong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2017年 / 8卷
关键词
V gamma 9V delta 2-T cells; antitumor activity; pro-tumor activity; tumor immunity; tumor immunotherapy; DELTA-T-CELLS; TCR-GAMMA-DELTA; PRENYL PYROPHOSPHATE ANTIGENS; BREAST-CANCER PATIENTS; EPSTEIN-BARR-VIRUS; PERIPHERAL-BLOOD; ADOPTIVE IMMUNOTHERAPY; IMMUNE-RESPONSES; ZOLEDRONIC ACID; DENDRITIC-CELLS;
D O I
10.3389/fimmu.2017.01041
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2-T cells are considered as potent effector cells for tumor immunotherapy through directly killing tumor cells and indirectly regulating other innate and adaptive immune cells to establish antitumoral immunity. The antitumoral activity of V gamma 9V delta 2-T cells is governed by a complicated set of activating and inhibitory cell receptors. In addition, cytokine milieu in tumor microenvironment can also induce the pro-tumoral activities and functional plasticity of V gamma 9V delta 2-T cells. Here, we review the anti-versus pro-tumoral activities of V gamma 9V delta 2-T cells and discuss the mechanisms underlying the recognition, activation, differentiation and regulation of V gamma 9V delta 2-T cells in tumor immunosurveillance. The comprehensive understanding of the dual face of V gamma 9V delta 2-T cells in tumor immunology may improve the therapeutic efficacy and clinical outcomes of V gamma 9V delta 2-T cell-based tumor immunotherapy.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts
    Gertner-Dardenne, Julie
    Castellano, Remy
    Mamessier, Emilie
    Garbit, Slaveia
    Kochbati, Eloise
    Etienne, Anne
    Charbonnier, Aude
    Collette, Yves
    Vey, Norbert
    Olive, Daniel
    JOURNAL OF IMMUNOLOGY, 2012, 188 (09) : 4701 - 4708
  • [22] Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?
    Kuenkele, Klaus-Peter
    Wesch, Daniela
    Oberg, Hans-Heinrich
    Aichinger, Martin
    Supper, Verena
    Baumann, Christoph
    CELLS, 2020, 9 (04)
  • [23] Adoptive Immunotherapy of Epithelial Ovarian Cancer with Vγ9Vδ2 T Cells, Potentiated by Liposomal Alendronic Acid
    Parente-Pereira, Ana C.
    Shmeeda, Hilary
    Whilding, Lynsey M.
    Zambirinis, Constantinos P.
    Foster, Julie
    van der Stegen, Sjoukje J. C.
    Beatson, Richard
    Zabinski, Tomasz
    Brewig, Nancy
    Sosabowski, Jane K.
    Mather, Stephen
    Ghaem-Maghami, Sadaf
    Gabizon, Alberto
    Maher, John
    JOURNAL OF IMMUNOLOGY, 2014, 193 (11) : 5557 - 5566
  • [24] Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire
    Dimova, Tanya
    Brouwer, Margreet
    Gosselin, Francoise
    Tassignon, Joel
    Leo, Oberdan
    Donner, Catherine
    Marchant, Arnaud
    Vermijlen, David
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (06) : E556 - E565
  • [25] Phenotypic and functional characterization of pharmacologically expanded Vγ9Vδ2 T cells in pigtail macaques
    Barber-Axthelm, Isaac M.
    Wragg, Kathleen M.
    Esterbauer, Robyn
    Amarasena, Thakshila H.
    Barber-Axthelm, Valerie R. B.
    Wheatley, Adam K.
    Gibbon, Anne M.
    Kent, Stephen J.
    Juno, Jennifer A.
    ISCIENCE, 2023, 26 (03)
  • [26] Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion
    King, Lisa A.
    de Jong, Milon
    Veth, Myrthe
    Hulsik, David Lutje
    Yousefi, Parsa
    Iglesias-Guimarais, Victoria
    van Helden, Pauline M.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting Vγ9Vδ2 T Cells for the Treatment of Hematologic Malignancy
    Kalyan, S.
    Wesch, D.
    Kabelitz, D.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (34) : 5206 - 5216
  • [28] Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells
    Liu, Meng
    Sun, Ling-ling
    Li, Ying-jun
    Li, Heng-yuan
    Zhang, Jian
    Li, Bing-hao
    Ye, Zhao-ming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2015, 28 (01) : 160 - 167
  • [29] Activated Vγ9Vδ2 T Cells Trigger Granulocyte Functions via MCP-2 Release
    Agrati, Chiara
    Cimini, Eleonora
    Sacchi, Alessandra
    Bordoni, Veronica
    Gioia, Cristiana
    Casetti, Rita
    Turchi, Federica
    Tripodi, Marco
    Martini, Federico
    JOURNAL OF IMMUNOLOGY, 2009, 182 (01) : 522 - 529
  • [30] Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid
    Inoue, Yusuke
    Oda, Asuka
    Maeda, Yusaku
    Sumitani, Ryohei
    Oura, Masahiro
    Sogabe, Kimiko
    Maruhashi, Tomoko
    Takahashi, Mamiko
    Fujii, Shiro
    Nakamura, Shingen
    Miki, Hirokazu
    Hiasa, Masahiro
    Teramachi, Jumpei
    Harada, Takeshi
    Abe, Masahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (06) : 626 - 630